Custom Criteria for
BlueCross Blue Shield of Rhode Island Commercial

MYOBLOC® (rimabotulinumtoxinB)

GPI CODING:

74400020******

DESCRIPTION:

RimabotulinumtoxinB (MYOBLOC®) is a botulinum neurotoxin product produced by the spore-forming anaerobic bacillus *Clostridium botulinum* type B (Bean strain). Botulinum toxins inhibit the release of acetylcholine from cholinergic junctions, causing functional denervation of the muscle that result in a localized reduction of muscle activity. Botulinum toxin, type B specifically cleaves synaptic vesicle associated membrane protein (VAMP, synaptobrevin). Synaptobrevin is a component of the protein complex responsible for docking and fusion of the synaptic vesicle to the presynaptic membrane, which is a key step to neurotransmitter (acetylcholine) release.

APPROVAL DURATION:

Initial approvals and renewals: 12 months.

CRITERIA FOR MYOBLOC:

I. Patient has a diagnosis for one of the following:
   A. Cervical dystonia (including spasmodic torticollis) OR
   B. Sialorrhea (drooling/ptyalism or excessive salivation) associated with neurological disorders (i.e. amyotrophic lateral sclerosis, cerebral palsy, Parkinson's disease)
II. Patient does not have any of the following contraindications to therapy
   A. Hypersensitivity to human albumin
   B. Presence of infection at the proposed injection site(s)

Authorization for continued use shall be reviewed at least every 12 months to confirm that current coverage policy criteria are met.